OpGen (OPGN) Reaches New 1-Year High and Low at $1.62

OpGen Inc (NASDAQ:OPGN)’s share price hit a new 52-week high and low during trading on Wednesday . The stock traded as low as $1.62 and last traded at $1.70, with a volume of 30856 shares trading hands. The stock had previously closed at $1.63.

OPGN has been the topic of several analyst reports. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. ValuEngine upgraded OpGen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright set a $9.00 price target on OpGen and gave the company a “buy” rating in a report on Thursday.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Thursday, March 15th. The medical research company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.05. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.81 million. OpGen had a negative net margin of 479.38% and a negative return on equity of 2,118.30%. analysts anticipate that OpGen Inc will post -2.31 earnings per share for the current fiscal year.

An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. lifted its stake in OpGen Inc (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 at the end of the most recent reporting period.

ILLEGAL ACTIVITY WARNING: “OpGen (OPGN) Reaches New 1-Year High and Low at $1.62” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3334846/opgen-opgn-reaches-new-1-year-high-and-low-at-1-62.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Anticipate Solaris Oilfield Infra  Will Post Quarterly Sales of $33.23 Million
Zacks: Brokerages Anticipate Solaris Oilfield Infra Will Post Quarterly Sales of $33.23 Million
BSB Bancorp  Releases Quarterly  Earnings Results
BSB Bancorp Releases Quarterly Earnings Results
Line  Downgraded to Underperform at Jefferies Group
Line Downgraded to Underperform at Jefferies Group
Advanced Micro Devices  Given New $9.00 Price Target at Barclays
Advanced Micro Devices Given New $9.00 Price Target at Barclays
Redcentric  Receives Hold Rating from Numis Securities
Redcentric Receives Hold Rating from Numis Securities
Las Vegas Sands  Price Target Raised to $84.00 at Morgan Stanley
Las Vegas Sands Price Target Raised to $84.00 at Morgan Stanley


© 2006-2018 Ticker Report. Google+.